CFM
CRBP icon

Catalyst Funds Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Catalyst Funds Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,149
Closed -$128K – 387
2025
Q3 		$128K Buy
+10,149
New +$96.5K 0.02% 450

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Catalyst Funds Management's CRBP Position: Q4 2025 in Review

Catalyst Funds Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2025, closing a stake of 10,149 shares — an estimated $128K sold.

Catalyst Funds Management first reported a position in CRBP in Q3 2025 and held it in 1 quarter. The position peaked at $128K in Q3 2025. 100 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

  • Catalyst Funds Management reported no remaining Corbus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 10,149 Corbus Pharmaceuticals shares in Q4 2025, an estimated $128K.
  • Catalyst Funds Management first reported a position in Corbus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Catalyst Funds Management's Corbus Pharmaceuticals position peaked at $128K in Q3 2025.
  • 100 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on Catalyst Funds Management's 13F filing for Q4 2025, filed 9 Feb 2026.